SOHO 2020 Scientific Program

The Society of Hematologic Oncology's Eighth Annual Meeting is scheduled for September 9-12, 2020. The focus of the 3.5-day program is state-of-the-art approaches in the field of hematologic malignancies. The meeting includes a variety of educational formats including: general sessions, meet-the-professor sessions, breakfast with the expert, debates, plenary sessions and a number of informal events. SOHO members have early access to session selections. To sign-up for FREE SOHO membership, go to the SOHO membership site.

You may view the SOHO 2020 session line-up in the Program-at-a-Glance, the detailed program by day or download a copy of the program in PDF format.

 

PROGRAM-AT-A-GLANCE

 

SOHO 2020 PROGRAM

TIME TOPIC/SESSION SPEAKER AFFILIATION/ROOM
MEET-THE-PROFESSOR SESSION I    
6:45 AM MTP Session I: AML    
  Session Chair: Catherine Smith    
  IDH Inhibition Stéphane De Botton, MD Institut deCancérologie Gustave Roussy, Paris, France
  FLT3 Inhibition Catherine Smith, MD University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, California, USA
  Approaches to Understand Mechanisms of Resistance and Response To AML Therapies Using Single Cell Approaches Vitae Paresh Vyas, MRCPath, FRCP, FRCPath Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom
6:45 AM MTP Session II: ALL    
  Session Chair: Ching-Hon Pui    
  How the COG is Approaching the High-Risk Patient with ALL – Incorporation of CAR-T into Frontline Therapy Jennifer McNeer, MD, MS The University of Chicago Medicine, Chicago, Illinois, USA
  Management of Asparaginase Toxicity in AYAs with ALL Kjeld  Schmiegelow, MD Copenhagen University Hospital, Copenhagen, Denmark
  How to Use a MRD Result in AYAs Receiving Pediatric Regimens? Aaron Logan, MD, PhD UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, USA
6:45 AM MTP Session III: NHL    
  Session Chair: Nathan Fowler    
  What is the Optimal Frontline Regimen in FL Nathan H. Fowler, MD The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
  CNS Lymphoma Christopher R Flowers, MD, MS The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
  Role of Transplant in Lymphoma Sonali M. Smith, MD, FASCO The University of Chicago, Chicago, Illinois, USA
6:45 AM MTP Session IV: NHL    
  Session Chair: Laurie Sehn    
  Double Hit Lymphoma Laurie Sehn, MD, MPH University of British Columbia, Vancouver, Canada
  CAR T-Cell Therapy for Lymphoma Sattva Neelapu, MD The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
  Hodgkin Lymphoma Pier Luigi Zinzani, MD University of Bologna, Bologna, Italy
6:45 AM MTP Session V: CML    
  Session Chair: Jerry Radich    
  Selecting the Right TKI Jorge Cortés, MD Georgia Cancer Center at Augusta University, Augusta, Georgia, USA
  CML Management in Resource Limited Countries Jerald P. Radich, MD University of Washington School of Medicine, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
  Is NGS Ready for Clinical Practice: Advantages and Limitations Simona Soverini, MD University of Bologna, Bologna, Italy
6:45 AM MTP Session VI: MPN    
  Session Chair: Uday Popat    
  CASE STUDIES IN MPN: WHEN IS TREATMENT NECESSARY?  
  A Young Woman with Thrombocytosis Prithviraj Bose, MD The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
  A Young Man with Polycythemia Vera and Fatigue Gabriela Hobbs, MD Massachusetts General Hospital, Boston, Massachusetts, USA
  A Mildly Symptomatic Middle-Aged Woman with INT-1 Primary Myelofibrosis Uday Popat, MD The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
6:45 AM MTP Session VII: MDS    
  Session Chair: Koichi Takahashi    
  The Spectrum of Clonal Hematopoiesis from CHIP to AML Koichi Takahashi, MD The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
  Challenges in Diagnosis and Risk Stratification of MDS Nazha Aziz, MD Cleveland Clinic, Cleveland, Ohio, USA
  Pitfalls in Assessing Response to Treatment in MDS Uwe Platzbecker, MD Medical Clinic and Policlinic 1, Hematology and Cellular Therapy, Leipzig University Hospital, Leipzig, Germany
6:45 AM MTP Session VIII: MM    
  Session Chair: Thomas Martin    
  Amyloidosis Suzanne Lentzsch, MD, PhD Columbia University and at New York Presbyterian Hospital, New York, USA
  Emerging Therapies Thomas G. Martin, MD University of California San Francisco, San Francisco, California, USA
6:45 AM MTP Session IX: CLL    
  Session Chair: Emili Montserrat    
  BTK and Monoclonal Antibodies Carol Moreno, MD, PhD Hospital de la Santa Creui Sant Pau, Autonomous University of Barcelona, Barcelona, Spain
  BTK and CIT Philip A. Thompson, MB, BS The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
  BTK and BCL2 Nitin Jain, MD The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
6:45 AM MTP Session X: CT    
  Session Chair: Susan Prockop    
  EBV CTLs for PTLD– Ready for Prime Time Susan Prockop, MD Memorial Sloan Kettering Cancer Center, New York, New York, USA
  CD19 CAR T Cells for Adults David L. Porter, MD University of Pennsylvania, Abramson Cancer Center, Philadelphia, Pennsylvania, USA
  Vaccines and Immunotherapy David E. Avigan, MD Beth Israel Deaconess Medical Center and Dana-Farber/Harvard Cancer Center, Boston, Massachusetts, USA
7:45 AM EXHIBIT HALL EXPERIENCE    
MEET-THE-PROFESSOR SESSION II    
8:00 AM MTP Session XI: AML    
  Session Chair: Courtney DiNardo    
  Venetoclax Daniel Pollyea, MD, MS University of Colorado, Denver, Colorado, USA
  Targeting the Microenvironment Geoffrey L. Uy, MD Washington University School of Medicine, St. Louis, Missouri, USA
  Familial AML Courtney D. DiNardo, MD, MSCE The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
8:00 AM MTP Session XII: ALL    
  Session Chair: Elias Jabbour    
  How I Approach the Treatment of T-ALL in Adults in 2020 Nitin Jain, MD The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
  How I Treat the Older Adult with B-ALL Elias Jabbour, MD The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
  How I Approach the Patient Who Has MRD Or Relapse After Transplant  Lori Muffly, MD Stanford University Medical Center, Palo Alto, California, USA
8:00 AM MTP Session XIII: NHL    
  Session Chair: Pier Luigi Zinzani    
  Primary Mediastinal Large Cell Lymphoma Pier Luigi Zinzani, MD University of Bologna, Bologna, Italy
  Role of Radiation Therapy in HL Joachim Yahalom, MD, FACR Memorial Sloan-Kettering Cancer Center, New York, New York, USA
  Chemo Free Regimens in Lymphoma Loretta Nastoupil, MD The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
8:00 AM MTP Session XIV:NHL    
  Session Chair: Ariela Noy    
  Novel Treatments for Aggressive Lymphoma Christopher R Flowers, MD, MS The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
  Treatment of Early Stage DLBCL Daniel O. Persky, MD University of Arizona Cancer Center, Tucson, Arizona, USA
  Burkitt Lymphoma Ariela Noy, MD Memorial Sloan-Kettering Cancer Center, New York, New York, USA
8:00 AM MTP Session XV: CML    
  Session Chair: Jerry Radich    
  Selecting the Right TKI Jorge Cortés, MD Georgia Cancer Center at Augusta University, Augusta, Georgia, USA
  CML Management in Resource Limited Countries Jerald P. Radich, MD University of Washington School of Medicine, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
  Is NGS Ready for Clinical Practice: Advantages and Limitations Simona Soverini, MD University of Bologna, Bologna, Italy
8:00 AM MTP Session XVI: MPN    
  Session Chair: Uday Popat    
  CASE STUDIES IN MPN: WHEN IS TREATMENT NECESSARY?  
  A Young Woman with Thrombocytosis Prithviraj Bose, MD The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
  A Young Man with Polycythemia Vera and Fatigue Gabriela Hobbs, MD Massachusetts General Hospital, Boston, Massachusetts, USA
  A Mildly Symptomatic Middle-Aged Woman with INT-1 Primary Myelofibrosis Uday Popat, MD The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
8:00 AM MTP Session XVII: MDS    
  Session Chair: Rami Komrokji    
  How Do I Treat: Lower Risk MDS Valeria Santini, MD University of Florence, Florence, Italy
  How Do I Treat: Higher Risk MDS Rami Komrokji, MD H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA
  How Do I Treat: MDS/MPN Eric Padron, MD H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA
8:00 AM MTP Session XVIII: MM    
  Session Chair: Morie Gertz    
  Waldenstroms Macroglobunemia Sheeba K. Thomas, MD The University of Texas MD Anderson Cancer Center, Houston, TX, USA
  Bone Diseases and Supportive Care Jens Hillengass, MD Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA
8:00 AM MTP Session XIX: CLL    
  Session Chair: Phil Thompson    
  Managing BTK Inhibitor Toxicities Alessandra Ferrajoli, MD The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
  Managing BCL2 Toxicities John Seymour, MBBS, FRACP, PhD Peter MacCallum Cancer Centre & the Royal Melbourne Hospital, Melbourne, Australia
  Managing Cellular Therapy Toxicities Jae Park, MD Memorial Sloan Kettering Cancer Center, New York, New York, USA
8:00 AM MTP Session XX: CT    
  Session Chair: Sergio Giralt    
  Point of Care CAR T Cells Marcos de Lima, MD UH Cleveland Medical Center, Cleveland, Ohio, USA
  CAR vs Transplant for NHL Richard Maziarz, MD Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, USA
  Role of CAR T Cells in Relapsed Myeloma Andrzej Jakubowiak, MD, PhD University of Chicago Medical Center, Chicago, Illinois, USA
9:00 AM EXHIBIT HALL EXPERIENCE    
TIME TOPIC/SESSION SPEAKER AFFILIATION/ROOM
SESSION I: ACUTE LYMPHOBLASTIC LEUKEMIA    
Session Chairs: Dieter Hoelzer and Wendy Stock    
9:15 AM Welcome and Opening Remarks Sagar Lonial, MD President, Society of Hematologic Oncology
9:25 AM In Relapsed B-ALL, How Should We Best Sequence the New Targeted Agents? Emily Curran, MD The University of Cincinnati, Cincinnati, Ohio, USA
9:40 AM Q & A    
9:43 AM Mini-Hyper – CVD Combinations for Older Adults: Results of Recent Trials and A Glimpse Into the Future Marlise R. Luskin, MD, MSCE Dana Farber Cancer Institute, Boston, Massachusetts, USA
9:58 AM Q & A    
10:01 AM Who Should Receive An Allogeneic Transplant in First Complete Remission? Josep-Maria Ribera, MD, PhD Catalan Institute of Oncology, Barcelona, Spain
10:16 AM Q & A    
10:19 AM What’s the Latest Innovation in CAR-T Therapy? Fast-Off, Dual Targeting and Other New Tricks Martin Pule, MD, PhD Cancer Institute, University College London, London, United Kingdom
10:34 AM Q & A    
10:37 AM Genomics of Drug Response in ALL: Predicting Response and Concerns for Triggering Relapse Jun J. Yang, PhD St. Jude Children's Research Hospital, Memphis, Tennessee, USA
10:52 AM Q & A    
10:55 AM DEBATE:Is Less more? Intensive vs Non-Intensive Approach To Adults with Ph+ ALL | Intensive Approach Nicholas Short, MD The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
11:10 AM Q & A    
11:13 AM DEBATE:Is Less More? Intensive vs Non-Intensive Approach To Adults with Ph+ ALL | Non-Intensive Approach Sabina Chiaretti, MD, PhD Sapienza University, Rome, Italy
11:28 AM Q & A    
11:31 AM Oral Abstract: ALL-312
Sixteen Years' Experience in Treating Adolescents and Young Adult (AYA) with Philadelphia-Negative Acute Lymphoblastic Leukemia (Ph- ALL) with a Modified Pediatric ALL Protocol
Saleem Eldadah, MD Princess Noorah Oncology Center, Ministry of the National Guard - Health Affairs, Jeddah, Saudi Arabia
INDUSTRY EXPERT SESSION I    
11:41 AM IDHIFA: The First and Only Oral, Targeted Inhibitor of IDH2 Hetty Carraway, MD, MBA Cleveland Clinic, Cleveland, Ohio, USA
  This activity is supported by Bristol-Myers Squibb    
INDUSTRY EXPERT SESSION IA    
11:41 AM TBD TBD  
  This activity is supported by Kite Pharma    
PLENARY SESSION I    
Session Chair: Sagar Lonial    
1:11 PM Keynote Speaker: Immunotherapy for T-Cell ALL and T-NHL John DiPersio, MD, PhD Washington University, St. Louis, Missouri, USA
  Recipient of the SOHO 2020 Distinguished Lecturer Award    
SESSION II: MYELODYSPLASTIC SYNDROMES    
Session Chairs: Guillermo Garcia-Manero and Valeria Santini    
1:31 PM New Approaches for Anemia in MDS Uwe Platzbecker, MD Medical Clinic and Policlinic 1, Hematology and Cellular Therapy, Leipzig University Hospital, Leipzig, Germany
1:46 PM Q & A    
1:49 PM Development of Oral HMAs for MDS Guillermo Garcia-Manero, MD The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
2:04 PM Q & A    
2:07 PM Targeting BCL-2 in MDS Amer Zeidan, MBBS Yale Cancer Center, New Haven, Connecticut, USA
2:22 PM Q & A    
2:25 PM Targeting p53 in MDS David Sallman, MD H. Lee Moffitt Cancer Center, Tampa, Florida, USA
2:40 PM Q & A    
2:43 PM IDH Inhibitors in MDS Courtney D. DiNardo, MD, MSCE The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
2:58 PM Q & A    
3:01 PM Oral Abstract: MDS-254
SF3B1 Splicing Mutation in the Context of Therapy-Related MDS
Virginia Volpe, MD H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA
3:11 PM BREAK    
SESSION III: ACUTE MYELOID LEUKEMIA    
Session Chairs: Richard Stone and Farhad Ravandi    
3:41 PM State of the Art in AML Laura C. Michaelis, MD Medical College of Wisconsin, Milwaukee, Wisconsin, USA
3:56 PM Q & A    
3:59 PM Germline Mutations in AML Coleman Lindsley, MD, PhD. Dana-Farber Cancer Institute, Boston, Massachusetts, USA
4:14 PM Q & A    
4:17 PM Harnessing Apoptosis in AML Marina Konopleva, MD, PhD The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
4:32 PM Q & A    
4:35 PM The Problem of Mutant P53 AML David Sallman, MD H. Lee Moffitt Cancer Center, Tampa, Florida, USA
4:50 PM Q & A    
4:53 PM TargetingCD123 in AML Andrew A. Lane, MD, PhD Dana-Farber Cancer Institute, Boston, Massachusetts, USA
5:08 PM Q & A    
5:11 PM DEBATE: Fit Older Adults Between 60-75  in First Remission On Either Extreme of the Prognostic Spectrum Should Undergo Allo SCT Uma Borate, MD, MS Oregon Health & Science University, Portland, Oregon, USA
5:26 PM Q & A    
5:29 PM DEBATE: Fit Older Adults Between 60-75  in First Remission On Either Extreme of the Prognostic Spectrum Should Not Undergo Allo SCT Edwin Pascal Alyea, MD Duke University School of Medicine, Durham, North Carolina, USA
5:44 PM Q & A    
5:47 PM Novel Antibodies in AML Marion Subklewe, MD Ludwig-Maximilians-University of Munich, Munich, Germany
6:02 PM Q & A    
6:05 PM Oral Abstract: AML-063
A Randomized, Double-Blind, Placebo-Controlled Study of Venetoclax with Azacitidine Versus Azacitidine in Treatment-Naïve Patients with Acute Myeloid Leukemia Ineligible for Intensive Therapy-Viale-A
Courtney D. DiNardo, MD, MSCE The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
6:15 PM ADJOURN    
POSTER SESSION & WELCOME RECEPTION    
6:15 PM POSTER SESSION    
6:15 PM WELCOME RECEPTION AND AWARDS    
INDEPENDENT SATELLITE SYMPOSIUM I    
8:15 PM Relapsed/Refractory Multiple Myeloma: What’s Next for Patients?  
  Jesus Berdeja, MD, Tennessee Oncology and Joshua Richter, MD, Mount Sinai
  This CME activity is jointly provided by Purdue University College of Pharmacy, RedMedEd, and the Multiple Myeloma Research Foundation. This activity is supported by educational grants from Amgen and Bristol-Myers Squibb. For more information and to register for this ISS, visit TBD.
       
TIME TOPIC/SESSION SPEAKER AFFILIATION/ROOM
INDEPENDENT SATELLITE SYMPOSIUM II    
6:15 AM The Evolving Treatment Landscape in Triple-Class Refractory Multiple Myeloma with a Specific Focus on B-Cell Maturation Antigen (BCMA) as a Promising Therapeutic Target
Sagar Lonial, MD, FACP | Emory University, Atlanta, USA – Chair 
Adam Cohen, MD | University of Pennsylvania, Philadelphia, USA | Shaji Kumar, MD | Mayo Clinic, Rochester, Minnesota, USA 

This Activity is supported by GlaxoSmithKline
BREAKFAST WITH THE EXPERT I    
6:45 AM CAR T for Myeloid Leukemias– Current Status Stephen J. Forman, MD City of Hope National Medical Center, Duarte, California, USA
7:45 AM EXHIBIT HALL EXPERIENCE    
SESSION IV: MYELOPROLIFERATIVE NEOPLASMS    
Session Chairs: Srdan Verstovsek and Laura Michaelis    
8:00 AM Genomics in Myelofibrosis: Practical Guidelines for Its Use in Clinical Practice Raajit K. Rampal, MD, PhD Memorial Sloan-Kettering Cancer Center, New York, New York, USA
8:15 AM Q & A    
8:18 AM New Therapies in Development for Myelofibrosis Srdan Verstovsek, MD, PhD The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
8:33 AM Q & A    
8:36 AM Improved Outcomes with Transplant for MPN Upday Popat, MD The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
8:51 AM Q & A    
8:54 AM CASE PRESENTATION: Thrombosis in PV: How To Predict and How To Reduce the Risk Gabriela Hobbs, MD Massachusetts General Hospital, Boston, Massachusetts, USA
9:09 AM Q & A    
9:12 AM CASE PRESENTATION: Post PV and Post ET MF: What A Doctor Needs To Know Laura C. Michaelis, MD Medical College of Wisconsin, Milwaukee, Wisconsin, USA
9:27 AM Q & A    
9:30 AM Oral Abstract: MPN-188
Myeloablative Fludarabine and Busulfan Regimen in Myelofibrosis (MF): Long-Term Outcomes and Analysis of Prognostic Factors
Joseph Jacinth, MD The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
9:40 AM EXHIBIT HALL EXPERIENCE    
SESSION V: MULTIPLE MYELOMA    
Session Chairs: Sagar Lonial and Thomas Martin    
10:10 AM Frontline Therapy for Frail Older Patients Brea C. Lipe, MD The University of Rochester, Rochester, New York, USA
10:25 AM Q & A    
10:28 AM DEBATE: Frontline Therapy for Fit MM Patients Should Include an Antibody Peter M. Voorhees, MD Levine Cancer Institute, Atrium Health, Charlotte, North Carolina, USA
10:43 AM Q & A    
10:46 AM DEBATE: Frontline Therapy for Fit MM Patients Should NOT Include an Antibody Thomas G. Martin, MD University of California San Francisco, San Francisco, California, USA
11:01 AM Q & A    
11:04 AM DEBATE: Smoldering MM Should Be Treated Early Maria-Victoria Mateos, MD, PhD University Hospital of Salamanca, Spain
11:19 AM Q & A
11:22 AM DEBATE: Smoldering MM Should NOT Be Treated Early Angela Dispenzieri, MD Mayo Clinic Rochester, Rochester, Minnesota, USA
11:37 AM Q & A    
11:40 AM Role of HDT in Current Treatment for MM Ajay K. Nooka, MD, MPH, FACP Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia, USA
11:55 AM Q & A    
11:58 AM Management of Early Relapse Robert Z. Orlowski, MD, PhD The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
12:13 PM Q & A    
12:13 PM Oral Abstract: MM-350
Daratumumab (DARA) + Lenalidomide/ Bortezomib/Dexamethasone (RVd) in African American/Black Patients (Pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Subgroup Analysis of GRIFFIN
Ajay K. Nooka, MD, MPH, FACP Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia, USA
INDUSTRY EXPERT SESSION II    
12:23 PM TBD TBD  
  This activity is supported by Novartis    
INDUSTRY EXPERT SESSION IIA    
12:23 PM Jakafi® (ruxolitinib) in Patients with Polycythemia Vera Who Have an Inadequate Response to Hydroxyurea: A Case-Based Presentation Kelly McCaul, MD  Avera Cancer Institute, Sioux Falls, South Dakota, USA
  This activity is supported by Incyte    
PLENARY SESSION II    
Session Chair: TBD    
1:53 PM BCMA Directed Therapy for MM Nikhil C. Munshi, MD Dana-Farber Cancer Institute, Boston, Massachusetts, USA
SESSION VI: CHRONIC LYMPHOCYTIC LEUKEMIA    
Session Chairs: Jennifer Brown and Florence Cymbalista    
2:13 PM Next Generation of BCR Inhibitors Paolo Ghia, MD, PhD Università Vita-Salute San Raffaele, Milano, Italy
2:28 PM Q & A    
2:31 PM Measuring Residual Disease, Clinical Implications William Wierda, MD The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
2:46 PM Q & A    
2:49PM BREAK    
3:19 PM What Is Fitness in the Era of Targeted Agents Alessandra Tedeschi, MD Niguarda Cancer Center, ASST Grande Ospedale Metropolitan Niguarda, Milan, Italy
3:34 PM Q & A    
3:37 PM Debate: BTK Inhibitor Is the Best Frontline Option for CLL John C. Byrd, MD The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA
3:52 PM Q & A    
3:55 PM Debate:BCL2 Inhibitor Is the Best Frontline Option for CLL Michael Hallek, MD University of Cologne, Cologne, Germany
4:10 PM Q & A    
4:13 PM Cellular Therapies in CLL Elizabeth J. Shpall, MD The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
4:28 PM Q & A    
4:31PM Oral AbstractCLL-091
Acalabrutinib Versus Idelalisib Plus Rituximab (IdR) or Bendamustine Plus Rituximab (BR) in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): ASCEND Final Results
Paolo Ghia, MD, PhD Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milano, Italy
4:41 PM ADJOURN    
INDUSTRY EXPERT SESSION III    
4:41 PM A Treatment Option for Adult Patients with Newly Diagnosed CP Ph+ CML or Patients Resistant/Intolerant to Prior TKI Therapy TBD  
  This activity is supported by Pfizer    
INDUSTRY EXPERT SESSION IV    
5:41PM A Case-Based Discussion on Improving Outcomes in Patients with Newly-Diagnosed Secondary AML Usama Gergis, MD, MBA Weill Cornell Medical College, New York, New York, USA
  This activity is supported by Jazz Pharmaceuticals Inc.    
INDEPENDENT SATELLITE SYMPOSIUM III    
6:41 PM Managing MPNs: Staying on Track in a Rapidly Changing Treatment Landscape
Prithviraj Bose, MD; Ruben Mesa, MD; Raajit K. Rampal, MD, PhD
This CME Activity is provided by MediCom Worldwide, Inc. This activity is supported by educational grants from Bristol-Myers Squibb and Incyte.
For more information and to register for this ISS, go to TBD.
TIME TOPIC/SESSION SPEAKER AFFILIATION/ROOM
INDEPENDENT SATELLITE SYMPOSIUM IV    
6:15 AM Achieving Innovation in CLL Care with BTK Inhibitors: Selection, Safety, and Sequencing Across the Disease Continuum
Speakers: TBD
This CME activity is jointly provided by Penn State College of Medicine and PVI, PeerView Institute for Medical Education.
This activity is supported by an independent educational grant from AstraZeneca.
For more information and to register for the live ISS, go to PeerView.com/CLL20Live
For more information and to register for the live webcast, go to PeerView.com/CLL20Livewebcast
BREAKFAST WITH THE EXPERT II    
6:45 AM How to Move Beyond RCHOP Sandeep S. Dave, MD, MS Duke University School of Medicine, Durham, North Carolina, USA
7:45 AM EXHIBIT HALL EXPERIENCE    
SESSION VII: HODGKIN LYMPHOMA    
Session Chairs: David Straus    
8:00 AM Newly Diagnosed HL David J. Straus, MD Memorial Sloan-Kettering Cancer Center, New York, New York, USA
8:15 AM Q & A    
8:18 AM Relapsed HL Alex F. Herrera, MD City of Hope, Duarte, California, USA
8:33 AM Q & A    
8:36 AM Oral AbstractHL-323
Outcomes of First-Line Treatment in Patients with Advanced Clinical Stage Classic Hodgkin Lymphoma and Human Immunodeficiency Virus Infection
Juan José Del Moral, MD Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán
SESSION VIII: T-CELL LYMPHOMA    
Session Chairs: Steven Horwitz and Francisco Vega    
8:46 AM Pathology and Pathogenesis of T Cell Lymphoma Francisco Vega, MD PhD The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
9:01 AM Q & A    
9:04 AM Newly Diagnosed Kerry Savage, MD University of British Columbia, Vancouver, Canada
9:19 AM Q & A    
9:22 AM Relapsed T Cell Lymphoma Steven M. Horwitz, MD, PhD Memorial Sloan-Kettering Cancer Center, New York, New York, USA
9:37 AM Q & A    
9:40 AM Oral Abstract: TCL-127
Impact of Concomitant Steroids on Mogamulizumab Efficacy in MAVORIC
Larisa Geskin, MD New York Presbyterian Hospital, New York, NY, USA
9:50 AM EXHIBIT HALL EXPERIENCE    
SESSION IX: INDOLENT B-CELL LYMPHOMA    
Session Chairs: Mathias Rummel and Nathan Fowler    
10:20 AM Management of Newly Diagnosed FL Mathias J. Rummel, MD, PhD Justus-Liebig University-Hospital, Giessen, Germany
10:35 AM Q & A    
10:38 AM Relapsed FL Nathan H. Fowler, MD The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
10:53 AM Q & A    
10:56 AM Marginal Zone Lymphoma Emanuele Zucca, MD Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
11:11 AM Q & A    
11:14 AM Waldenstrom Mathias J. Rummel, MD, PhD Justus-LiebigUniversity-Hospital, Giessen, Germany
11:29 AM Q & A    
11:32 AM Oral Abstract: IBCL-344
Marginal Zone Lymphoma: Epidemiology and Outcomes in a Mexican Center
Rosana Córdova, MD  Instituto Nacional de Cancerología, Mexico City, Mexico
INDUSTRY EXPERT SESSION V    
11:42 AM TBD TBD  
  This activity is supported by Janssen    
INDUSTRY EXPERT SESSION VA    
11:42 AM Understanding YESCARTA® (axicabtagene ciloleucel) CAR T Therapy TBD  
  This activity is supported by Kite Pharma    
PLENARY SESSION III    
Session Chair: Hagop Kantarjian    
1:12 PM My Take on Prognostication and Management of Essential Thrombocythemia Ayalew Tefferi, MD Mayo Clinic Rochester, Rochester, Minnesota, USA
SESSION X: AGGRESSIVE B-CELL LYMPHOMA    
Session Chairs: Martin Hutchings and Sonali Smith    
1:32 PM Novel Immunotherapeutic Agents in Aggressive B-NHL Martin Hutchings, MD, PhD The Finsen Center, National Hospital Copenhagen University Hospital, Copenhagen, Denmark
1:47 PM Q & A    
1:50 PM Relapsed DLBCL Sonali M. Smith, MD, FASCO The University of Chicago, Chicago, Illinois, USA
2:05 PM Q & A    
2:08 PM CAR T Cells Peter Riedell, MD University of Chicago Medicine, Chicago, Illinois, USA
2:23 PM Q & A    
2:26 PM Oral Abstract: ABCL-256
Role of Radiotherapy Differs Between Stages for Primary Bone Large B-Cell Lymphoma in the Rituximab Era: A Real-World Study
Shengling Ma, MD Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
2:36 PM EXHIBIT HALL EXPERIENCE    
SESSION XI: MANTLE CELL LYMPHOMA    
Session Chair: Robert Marcus    
3:06 PM Frontline Treatment of Mantle Cell Lymphoma Steven LeGouill, MD, PhD Nantes University Hospital, Nantes, France
3:21 PM Q & A    
3:24 PM Relapsed MCL   Jonathon B. Cohen
MD, MS
Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia, USA
3:39 PM Q & A    
3:42 PM Oral AbstractMCL-129
First-Line Ibrutinib Plus Venetoclax in MCL for Older Patients or Those with a TP53 Mutation: Ongoing Open-Label Arm of the PCYC-1143 Phase 3 SYMPATICO Study
Michael L. Wang, MD  The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
SESSION XII: CELLULAR THERAPY    
Session Chairs: Renier Brentjens and Sergio Giralt    
3:52 PM Adding Vaccines to the Immunotherapy Cocktail David E. Avigan, MD Beth Israel Deaconess Medical Center and Dana-Farber/Harvard Cancer Center, Boston, Massachusetts, USA
4:07 PM Q & A    
4:10 PM New CAR Designs Renier J. Brentjens, MD, PhD Memorial Sloan-Kettering Cancer Center, New York, New York, USA
4:25 PM Q & A    
4:28 PM Optimizing Lymphodepletion Prior to CAR T Cell Therapy   Elizabeth L. Budde, MD, PhD City of Hope National Medical Center, Duarte, California, USA
4:43 PM Q & A    
4:46 PM Oral Abstract: CT-279
Story of Success of Haploidentical Hematopoietic Stem Cell Transplantation in Aplastic Anemia: A Systematic Review and Meta-Analysis of Clinical Outcome
Ghada ELGohary, MD Ain Shams University, Cairo, Egypt
4:56 PM ADJOURN    
INDUSTRY EXPERT SESSION VI    
4:56 PM XOSPATA® (gilteritinib): A Targeted Therapeutic Approach for Relapsed/Refractory FLT3m+ AML Patients Naval Daver, MD The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
  This activity is supported by Astellas    
INDUSTRY EXPERT SESSION VII    
5:56 PM A Therapeutic Option for R/R DLBCL, NOS, After at Least Two Prior Therapies: Study Results from a Randomized Trial Cyrus Khan, MD Allegheny Health Network Cancer Institute, Pittsburgh, Pennsylvania, USA
  This activity is supported by Genentech    
INDEPENDENT SATELLITE SYMPOSIUM V    
6:56 PM Treating Multiple Myeloma in 2020 – Best Approaches to Optimizing Patient Outcomes
  This CME activity is jointly provided by the University of Nebraska Medical Center, Center for Continuing Education and Bio Ascend. 
This activity is supported by an educational grant from GlaxoSmithKline and Oncopeptides.
For more information and to register for this ISS, go to TBD.
TIME TOPIC/SESSION SPEAKER AFFILIATION/ROOM
INDEPENDENT SATELLITE SYMPOSIUM VI    
6:15 AM

Understanding Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Evolving Molecular Insights and Diagnosis of an Aggressive Hematologic Malignancy

TBD

This activity is supported by Stemline

BREAKFAST WITH THE EXPERT III    
6:45 AM CML Update Michael Deininger, MD, PhD Huntsman Cancer Hospital, The University of Utah, Salt Lake City, Utah, USA
7:45 AM EXHIBIT HALL EXPERIENCE    
SESSION XIII: CHRONIC MYELOID LEUKEMIA    
Session Chairs: Jorge Cortés and Simona Soverini    
8:00 AM CML: State of the Art Update Delphine Rea, MD, PhD Hôpital Saint Louis, Paris, France
8:15 AM Q & A    
8:18 AM New Therapeutic Options in CML Jorge Cortés, MD Georgia Cancer Center at Augusta University, Augusta, Georgia, USA
8:33 AM Q & A    
8:36 AM Update on CML-Like Disorders Nick Cross, MA, PhD, FRCPath University of Southampton, Salisbury, United Kingdom
8:51 AM Q & A    
8:54 AM Case Studies: the Challenges of TFR Timothy P. Hughes, MD, FRACP, FRCPA South Australian Health and Medical Research Institute, Adelaide, Australia
9:09 AM Q & A    
9:12 AM The Molecular Complexity of CML Jerald P. Radich, MD University of Washington School of Medicine, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
9:27 AM Q & A    
9:30 AM Oral Abstract: CML-109
Exploratory Biomarker Analysis From ENESTnd: Gene Expression Signature Distinguishes Deep Molecular Response (DMR) From Poor Response in Chronic Myeloid Leukemia (CML)
Jerald P. Radich, MD University of Washington School of Medicine, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
9:40 AM EXHIBIT HALL EXPERIENCE    
SESSION XIV: NEXT QUESTIONS    
Session Chairs: Sagar Lonial and Selina Luger    
10:10 AM Next Questions: Acute Lymphoblastic Leukemia Selina M. Luger, MD University of Pennsylvania, Abramson Cancer Center, Philadelphia, Pennsylvania, USA
10:20 AM Next Questions: Acute Myeloid Leukemia Amer Zeidan, MBBS Yale Cancer Center, New Haven, Connecticut, USA
10:30 AM Next Questions: Cellular Therapy Sergio Giralt, MD Memorial Sloan-Kettering Cancer Center, New York, New York, USA
10:40 AM Next Questions: Chronic Lymphocytic Leukemia Jennifer R. Brown, MD, PhD Dana-Farber Cancer Institute, Boston, Massachusetts, USA
10:50 AM Next Questions: Chronic Myeloid Leukemia Michael Deininger, MD, PhD Huntsman Cancer Hospital, The University of Utah, Salt Lake City, Utah, USA
11:00 AM Next Questions: Aggressive B-Cell Lymphoma Sandeep S. Dave, MD, MS Duke University School of Medicine, Durham, North Carolina, USA
11:10 AM Next Questions: Indolent B-Cell Lymphoma Robert Marcus, MA, FRCP, FRCPath Leaders in Oncology Care, London, United Kingdom
11:20 AM Next Questions: T-Cell Lymphoma Kerry Savage, MD University of British Columbia, Vancouver, Canada
11:30 AM Next Questions: Mantle Cell Lymphoma Jonathon B. Cohen
MD, MS
Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia, USA
11:40 AM Next Questions: Hodgkin Lymphoma David J. Straus, MD Memorial Sloan-Kettering Cancer Center, New York, New York, USA
11:50 AM Next Questions: Multiple Myeloma Sagar Lonial, MD, FACP Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia, USA
12:00 PM Next Questions: Myelodysplastic Syndromes Guillermo Garcia-Manero, MD The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
12:10 PM Next Questions: Myeloproliferative Neoplasms Srdan Verstovsek, MD, PhD The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
12:20 PM CLOSING REMARKS    
12:35 PM ADJOURN